There were 148 press releases posted in the last 24 hours and 440,189 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image